Jason Li (@jason_p_li) 's Twitter Profile
Jason Li

@jason_p_li

Girl Dad x2, Husband, Son. Cardiology Fellow @UWCardiology. USC Internal Medicine @KeckMedicineUSC. Boston University School of Medicine @BUMedicine

ID: 1813601327936843776

calendar_today17-07-2024 15:48:18

11 Tweet

27 Takipçi

89 Takip Edilen

Jason Li (@jason_p_li) 's Twitter Profile Photo

Shout out to Dr. #MarcoGuazzi for his insightful editorial in regards to our manuscript on exercise physiology, oxygen pulse (#O2Pulse) and HFpEF! jacc.org/doi/10.1016/j.… Rajeev Malhotra JACC Journals UW Cardiology MGH Cardiovascular Research Center

Prof Kamlesh Khunti (@kamleshkhunti) 's Twitter Profile Photo

FINEARTS-HF Benefits of finerenone irrespective of concomitant use of an SGLT2i. Combined use of SGLT2i and a non-steroidal MRA may provide additive protection in HF with mildly reduced or preserved ejection fraction. Muthu Vaduganathan et al ahajournals.org/doi/10.1161/CI…

FINEARTS-HF

Benefits of finerenone irrespective of concomitant use of an SGLT2i. 

Combined use of SGLT2i and a non-steroidal MRA may provide additive protection in HF with mildly reduced or preserved ejection fraction.

<a href="/mvaduganathan/">Muthu Vaduganathan</a> et al 

ahajournals.org/doi/10.1161/CI…
JAMA Cardiology (@jamacardio) 's Twitter Profile Photo

In #HFpEF, the AMETHYST RCT found that verinurad, a novel urate transporter-1 inhibitor allopurinol lowered uric acid but did not improve peak VO2, symptoms, or cardiac structure/function compared to allopurinol monotherapy or placebo. Sanjiv J. Shah, MD JAMA Cardiology ja.ma/3U1N1zT

In #HFpEF, the AMETHYST RCT found that verinurad, a novel urate transporter-1 inhibitor allopurinol lowered uric acid but did not improve peak VO2, symptoms, or cardiac structure/function compared to allopurinol monotherapy or placebo. <a href="/HFpEF/">Sanjiv J. Shah, MD</a> <a href="/JAMACardio/">JAMA Cardiology</a> ja.ma/3U1N1zT